1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dostarlimab Cancer	iTeos Belgium SA	P1/2	CCC (51)
Dpx-Survivac Cancer	University Health Network, Toronto	P2	CCC (51)
Encorafenib Cancer	Strata Oncology	P2	CCC (51)
Itacitinib Cancer	Douglas Johnson	P2	CCC (51)
Omeprazole Cancer	Genentech, Inc.	P1	CCC (51)
Rifaldazine Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1	CCC (51)
Selinexor Cancer	University Health Network, Toronto	P2	CCC (51)
Vebreltinib Cancer	Apollomics Inc.	P2	CCC (51)
asp7517 Cancer	Astellas Pharma Global Development, Inc.	P1/2	CCC (50)
Avelumab Cancer	Inimmune Corporation	P3	CCC (50)
Belzutifan Cancer	Merck Sharp & Dohme LLC	P2	CCC (50)
Calderasib Cancer	Merck Sharp & Dohme LLC	P2	CCC (50)
es014 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (50)
fda022-bb05 Cancer	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	P2	CCC (50)
Gm-Csf Cancer	China-Japan Friendship Hospital	P2	CCC (50)
hs-20093 Cancer	Hansoh BioMedical R&D Company	P2	CCC (50)
Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain Cancer	Institut Bergonié	P2	CCC (50)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2	CCC (50)
Irpagratinib Cancer	Beijing InnoCare Pharma Tech Co., Ltd.	P2	CCC (50)
Losartan Cancer	Ain Shams University	P2	CCC (50)
mk-1084 Cancer	Merck Sharp & Dohme LLC	P2	CCC (50)
Neratinib Cancer	University Health Network, Toronto	P2	CCC (50)
NORVIR Cancer	DualityBio Inc.	P2	CCC (50)
np137 Cancer	Centre Leon Berard	P2	CCC (50)
qls31905 Cancer	Qilu Pharmaceutical Co., Ltd.	P2	CCC (50)
RVU120 Cancer	Ryvu Therapeutics SA	P2	CCC (50)
Sacituzumab Tirumotecan Cancer	Convalife (Shanghai) Co., Ltd.	P2	CCC (50)
Sotorasib Cancer	Amgen	P2	CCC (50)
Spartalizumab Cancer	University Hospital, Bordeaux	P2	CCC (50)
Tucatinib Cancer	OnKure, Inc.	P2	CCC (50)
zg005 Cancer	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P2	CCC (50)
anv419 Cancer	Anaveon AG	P1/2	CCC (49)
Copanlisib Cancer	National Cancer Institute (NCI)	P2	CCC (49)
Eflornithine Cancer	Aminex Therapeutics, Inc.	P1/2	CCC (49)
Ibrutinib Cancer	Jennifer Woyach	P1/2	CCC (49)
Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4) Cancer	Tasly Pharmaceutical Group Co., Ltd	P1/2	CCC (49)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Cancer	Institut Curie	P2	CCC (49)
[177lu]lu-sn201 Cancer	Spago Nanomedical AB	P1/2	CCC (48)
[18F]Fluoropivalate Cancer	University College, London	P2	CCC (48)
Adapt-001 Cancer	EpicentRx, Inc.	P2	CCC (48)
Adavosertib Cancer	AstraZeneca	P2	CCC (48)
Allogeneic Tumour Lysate Cancer	Elios Therapeutics, LLC	P2	CCC (48)
Amxi-5001 Cancer	AtlasMedx, Incorporated	P1/2	CCC (48)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Cancer	Shanghai Miracogen Inc.	P1/2	CCC (48)
Apg 115 Cancer	Ascentage Pharma Group Inc.	P1/2	CCC (48)
asp2998 Cancer	Astellas Pharma Global Development, Inc.	P1/2	CCC (48)
bat1006 Cancer	Bio-Thera Solutions	P1/2	CCC (48)
bat4706 Cancer	Bio-Thera Solutions	P1/2	CCC (48)
CAN016 Cancer	Canwell Biotech Limited	P1/2	CCC (48)
Capmatinib Cancer	Cancer Research UK	P2/3	CCC (48)

Showing 201 to 250 of 1,380 assets

PreviousPage 5 of 28Next